Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Discovery of key protein’s shape could lead to improved bacterial pneumonia vaccine


St. Jude finding gives insights into how pneumonia bacteria ‘hijack’ a molecular shuttle that carries antibodies from the bloodstream and use this shuttle to invade the body

Scientists at St. Jude Children’s Research Hospital have discovered that the shape of a protein on the surface of pneumonia bacteria helps these germs invade the human bloodstream. This finding, published Dec. 16 online by the EMBO Journal, could help scientists develop a vaccine that is significantly more effective at protecting children against the disease.

The St. Jude researchers determined the shape of a large, paddle-like molecule that Streptococcus pneumoniae bacteria use to latch onto cells lining the throat and lungs. The protein, called CbpA, binds to a molecule on the cell called pIgR, which takes antibodies from the bloodstream on one side of the cell and transports them to the other side. There it releases the antibody at the lining of the throat and lungs. If a pneumococcus bacterium is hovering on the lining of the respiratory tract, this germ binds to pIgR and pushes this antibody shuttle back through the cell to the bloodstream. Once at the other side of the cell, the pneumococcus breaks free of pIgR and enters the blood, where it can multiply and infect the body.

S. pneumoniae is the only bacterium known to use CbpA to invade human cells by binding to pIgR, according to Richard W. Kriwacki, Ph.D., associate member of St. Jude Structural Biology. Kriwacki is senior author of the EMBO Journal report. "The fact that we now know the structure of this important protein means we can begin to develop a vaccine that is more effective in children than those that are currently available," Kriwacki said.

Elaine Tuomanen, M.D., chair of Infectious Diseases and director of the Children’s Infection Defense Center at St. Jude, is co-author of the EMBO Journal paper.

"Using CbpA as the key part of a new vaccine against S. pneumoniae would solve a problem that now hinders our ability to protect children from this infection," Tuomanen said.

Current pneumonia vaccines designed to protect adults against more than two dozen strains of S. pneumoniae do not work in young children. Adult vaccines are composed of pieces of carbohydrates naturally appearing on the surface of these bacteria. When used in a vaccine, these pieces of carbohydrate stimulate the immune system to make antibodies against the real carbohydrate targets on the bacteria. The problem with such vaccines is that the immune systems of very young children (younger than two years) do not naturally respond to carbohydrates. Pneumococcus vaccines for children must instead be modified by binding those carbohydrates to special proteins that stimulate the immune systems of young children.

"However such vaccines are so complex that they can carry carbohydrate targets for only a few specific strains of pneumonia bacteria," Tuomanen said. "So children are always under-protected, since there are so many different strains of these bacteria."

Knowing the shape of CbpA will guide researchers in their efforts to use part or all of this protein as the basis of a vaccine against S. pneumoniae. "CbpA is a very large protein," Tuomanen said. "Now that we know what it looks like and how it’s put together, we can pull it apart to see if smaller pieces of it can be used to make a vaccine that triggers production of antibodies against the CbpA. Since all the S. pneumoniae strains need CbpA to invade the bloodstream, we can widen the protection of a vaccine to all 90 types of pneumococcus by just adding CbpA, or a piece of CbpA."

The discovery of the structure of CbpA was a two-step process that included studies of how this protein works, followed by determination of its actual structure using powerful laboratory tools.

Previous work by another team suggested that CbpA binds to pIgR. However, that finding was made in "test-tube" experiments without using actual bacteria. So the St. Jude team developed pneumococcus bacteria that had mutated CbpA in order to prove that live bacteria with mutated CbpA could not bind to pIgR on cells. "Our work confirmed that the pneumococcus uses CbpA to bind to human cells," said Beth Mann, a research laboratory specialist in Tuomanen’s lab who developed the bacteria carrying mutated CbpA. Mann, co-author of the paper, also showed that the long, paddle-shaped extensions of the protein must be folded in a specific way in order for CbpA to work.

The discovery of the actual shape of CbpA was made using nuclear magnetic resonance (NMR) spectroscopy and circular dishroism (CD). NMR combines radio wave emissions and a powerful magnetic field to determine the structure of proteins suspended in solutions, while CD measures differences in the absorption of different types of polarized light by molecules to determine their shape. It also can show how that shape can change when the protein interacts with another molecule. "This work required that we develop new NMR methods in order to determine the shape of this protein, which undergoes changes as it interacts with pIgR," said Rensheng Luo, Ph.D., a post-doctoral fellow in St. Jude Structural Biology and Infectious Diseases and first author of the paper.

Other authors of the paper are William S. Lewis, Richard Heath, Siva Sivakolundu, Eilyn R. Lacy (St. Jude); Arthur Rowe (University of Nottingham, Leicestershire, UK); Agnes E. Hamburger (California Institute of Technology, Pasadena, Calif.) and Pamela J. Bjorkman (Howard Hughes Medical Institute, California Institute of Technology).

Bonnie Cameron | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>